Scientists Explain Why Ovarian Cancer Stops Responding to Some Chemotherapy Treatments

Scientists Explain Why Ovarian Cancer Stops Responding to Some Chemotherapy Treatments
Increased expression of the ABCB1 protein, which is known to induce resistance to Adriamycin (doxorubicin) and Abraxane (paclitaxel) in ovarian cancer patients, may also cause resistance to other ovarian cancer treatments. The study, “ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells,” published in the British Journal of Cancer, suggests

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *